Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Kurtz JE, et al. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29. J Clin Oncol. 2023. PMID: 37643382 Free PMC article. Clinical Trial.
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Vergote I, et al. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. J Clin Oncol. 2023. PMID: 37669480 Clinical Trial.
Clinical management of primary vulvar cancer.
Woelber L, Kock L, Gieseking F, Petersen C, Trillsch F, Choschzick M, Jaenicke F, Mahner S. Woelber L, et al. Among authors: trillsch f. Eur J Cancer. 2011 Oct;47(15):2315-21. doi: 10.1016/j.ejca.2011.06.007. Epub 2011 Jul 4. Eur J Cancer. 2011. PMID: 21733674 Review.
Lost in effusion.
Trillsch F, Aberle J, Regier M, Choschzick M, Mahner S. Trillsch F, et al. Lancet. 2012 Aug 11;380(9841):620. doi: 10.1016/S0140-6736(12)60323-7. Lancet. 2012. PMID: 22883511 No abstract available.
Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J. Fotopoulou C, et al. Among authors: trillsch f. Ann Surg Oncol. 2013 Apr;20(4):1348-54. doi: 10.1245/s10434-012-2673-z. Epub 2012 Oct 2. Ann Surg Oncol. 2013. PMID: 23054114
Adjuvant therapy in node-positive vulvar cancer.
Mahner S, Trillsch F, Kock L, Rohsbach D, Petersen C, Kruell A, Harter P, Jaenicke F, Woelber L. Mahner S, et al. Among authors: trillsch f. Expert Rev Anticancer Ther. 2013 Jul;13(7):839-44. doi: 10.1586/14737140.2013.811063. Expert Rev Anticancer Ther. 2013. PMID: 23875662 Review.
The prognostic significance of Jun transcription factors in ovarian cancer.
Eckhoff K, Flurschütz R, Trillsch F, Mahner S, Jänicke F, Milde-Langosch K. Eckhoff K, et al. Among authors: trillsch f. J Cancer Res Clin Oncol. 2013 Oct;139(10):1673-80. doi: 10.1007/s00432-013-1489-y. Epub 2013 Aug 13. J Cancer Res Clin Oncol. 2013. PMID: 23942796
123 results